Bristol's Yervoy Bursts Out Of The Gate
This article was originally published in The Pink Sheet Daily
The first-in-class immunotherapy for metastatic melanoma generated $95 million in its first full quarter on the market, exceeding management's expectations.
You may also be interested in...
Top-line results from the Phase III ARISTOTLE trial show the novel anticoagulant was superior to warfarin on safety and efficacy - a pleasant surprise for investors.
Bristol-Myers Squibb is using a "new customer model" that takes a holistic approach to supporting Yervoy (ipilimumab), CEO Lamberto Andreotti told analysts on the company's first-quarter earnings call on April 28.
Labeling does not specify line of therapy, so the melanoma drug could see use beyond very late-stage refractory patient population studied in pivotal trial.